Drugs Made In America Acquisition II (DMII) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 0 213 sessions, December 3, 2025 to November 6, 2026
- Largest daily move
- +0.5% close of December 19, 2025
- 1-month change
- +0.2% closing prices, October 6, 2026 to November 6, 2026
Company Description
Drugs Made In America Acquisition II (NASDAQ: DMII) is classified in the shell companies industry within the Financial Services sector and carries a market capitalization of $650.4M.
DMII has gained 3.1% so far this year. The last closing price was $10.21.
For FY2025, Drugs Made In America Acquisition II reported net income of $4.2M.
This page collects what Stock Titan holds for DMII, including price data, SEC filings, financial highlights, and short interest trends.
Stock Performance
Drugs Made In America Acquisition II (DMII) closed at $10.21 on November 6, 2026. So far this year, the price has gained 3.1%.
DMII Metrics & Rankings
Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
Drugs Made In America Acquisition II has filed 9 recent SEC filings, including 5 Form 8-K, 2 Form 10-Q, 1 Form 10-K, 1 Form NT 10-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMII SEC filings →
Financial Highlights
Drugs Made In America Acquisition II reported operating income of -$488K in FY2025, and net income was $4.2M. The company generated -$1.0M in operating cash flow. The current ratio was 0.09, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Drugs Made In America Acquisition II (DMII) currently stands at 111.2 thousand shares, down 8.5% from the previous reporting period, representing 0.2% of the float. Since December 2025, short interest has increased by 148.7%.
Days to Cover History
Days to cover for Drugs Made In America Acquisition II (DMII) currently stands at 1.0 days, down 52.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 159.6 days.
DMII Company Profile & Sector Positioning
Drugs Made In America Acquisition II (DMII) operates in the Shell Companies industry within the broader Financial Services sector and is listed on the NASDAQ.
Investors comparing DMII often look at related companies in the same sector, including Churchill Capital Corp XI (CCXI), EQV Ventures Acquisition Corp. II (EVAC), Bain Capital GSS Investment Corp. (BCSS), Cantor Equity Partners IV, Inc. (CEPF), and Churchill Capital Corp XII (CXII). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate DMII's relative position within its industry.